We are testing a new combination of siltuximab with standard chemotherapy for patients with poor prognosis AML. The goal is to see if this approach improves treatment outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Acute Myeloblastic Leukemia (AML) is a fast-growing cancer of the blood and bone marrow that affects the production of blood cells, leading to symptoms such as fatigue, frequent infections, and easy bruising or bleeding.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.